404 followers
RT @Daniel_E_Park: 3. SARS-CoV-2's nsp14 enzyme acts as a proofreader, reducing mutations ~10–50x vs influenza. That's why circulating vari…
RT @Daniel_E_Park: 3. SARS-CoV-2's nsp14 enzyme acts as a proofreader, reducing mutations ~10–50x vs influenza. That's why circulating vari…
RT @Daniel_E_Park: 3. SARS-CoV-2's nsp14 enzyme acts as a proofreader, reducing mutations ~10–50x vs influenza. That's why circulating vari…
3. SARS-CoV-2's nsp14 enzyme acts as a proofreader, reducing mutations ~10–50x vs influenza. That's why circulating variants remain antigenically close to JN.1. For now, there is no need to update the JN.1 strain, let alone add a second antigen or strain.…
SARS-CoV-2 Nsp14 mediates the effects of viral infection on the host cell transcriptome https://t.co/gTAZR1jzwt